Burgin 2020 Int J Mol Sci

From Bioblast
Revision as of 15:48, 6 April 2020 by Plangger Mario (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)
Publications in the MiPMap
Burgin HJ, Lopez Sanchez MIG, Smith CM, Trounce IA, McKenzie M (2020) Pioglitazone and deoxyribonucleoside combination treatment increases mitochondrial respiratory capacity in m.3243A>G MELAS cybrid cells. Int J Mol Sci 21:E2139.

Β» PMID: 32244971 Open Access

Burgin HJ, Lopez Sanchez MIG, Smith CM, Trounce IA, McKenzie M (2020) Int J Mol Sci

Abstract: The lack of effective treatments for mitochondrial disease has seen the development of new approaches, including those that aim to stimulate mitochondrial biogenesis to boost ATP generation above a critical disease threshold. Here, we examine the effects of the peroxisome proliferator-activated receptor Ξ³ (PPARΞ³) activator pioglitazone (PioG), in combination with deoxyribonucleosides (dNs), on mitochondrial biogenesis in cybrid cells containing >90% of the m.3243A>G mutation associated with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). PioG + dNs combination treatment increased mtDNA copy number and mitochondrial mass in both control (CON) and m.3243A>G (MUT) cybrids, with no adverse effects on cell proliferation. PioG + dNs also increased mtDNA-encoded transcripts in CON cybrids, but had the opposite effect in MUT cybrids, reducing the already elevated transcript levels. Steady-state levels of mature oxidative phosphorylation (OXPHOS) protein complexes were increased by PioG + dNs treatment in CON cybrids, but were unchanged in MUT cybrids. However, treatment was able to significantly increase maximal mitochondrial oxygen consumption rates and cell respiratory control ratios in both CON and MUT cybrids. Overall, these findings highlight the ability of PioG + dNs to improve mitochondrial respiratory function in cybrid cells containing the m.3243A>G MELAS mutation, as well as their potential for development into novel therapies to treat mitochondrial disease. β€’ Keywords: MELAS, OXPHOS, Cybrid, Deoxyribonucleosides, Mitochondrial biogenesis, Mitochondrial disease, Oxidative phosphorylation, Pioglitazone β€’ Bioblast editor: Plangger M β€’ O2k-Network Lab: AU Melbourne Trounce IA, AU Clayton St John J

Labels: MiParea: Respiration, mt-Biogenesis;mt-density, mtDNA;mt-genetics, Pharmacology;toxicology 

Stress:Mitochondrial disease  Organism: Human  Tissue;cell: Other cell lines  Preparation: Intact cells 

Coupling state: LEAK, ROUTINE, ET  Pathway: ROX  HRR: Oxygraph-2k 


Cookies help us deliver our services. By using our services, you agree to our use of cookies.